BRUSSELS (Reuters) - CureVac chief Franz-Werner Haas said on Thursday that preliminary trials on animals of the company’s COVID-19 vaccine candidate show it is effective against the UK and South African variants.
Haas told EU lawmakers that the results of the preliminary trials on the vaccine’s effects on variants would be published soon.
He also said that the company expected its vaccine to be approved in the European Union by June.
Reporting by Francesco Guarascio @fraguarascio; Editing by Susan Fenton
Our Standards: The Thomson Reuters Trust Principles.